SPOTLIGHT -
Slideshow
Author(s):
Although the clinical symptoms of psychotic disorders are dramatic and are what most clinicians focus on as their treatment targets, impairments in a wide range of cognitive function are observed in these illnesses.
FDA Committees Vote to Dismiss Clozapine REMS
Treating ‘Morally Objectionable’ Patients
Long-Acting Injectables and a Team-Driven Approach for Schizophrenia Treatment
What Will the Future of Alzheimer Disease Treatment Look Like?
Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in Phase 2 EMPOWER Trials
Schizophrenia Pharmacology: Version 2.0